Hello, welcome to Tosun!
会员中心

Product introduction:

Canagliflozin is a SGLT2 inhibitor drug, which can reduce blood sugar by removing glucose from the body through the kidney after glucose decomposition. In addition to good blood glucose control, canagliflozin (canagliflozin) has the most remarkable effect of weight loss and few hypoglycemic events, which has a broad prospect.


市场价:

  • Product information
  • 产品描述
  • 参数配置

1、 Product introduction

Chinese Name

English Name

Declaration TypeC

Department

Reportable Dosage Form

Declaration Progress

Strength

CAS
卡格列净  Canagliflozin5+3HypoglycemiaTablets

Ready to declare

100mg、300mg842133-18-0

Indication】

       For the treatment of type II diabetes in adult patients, not for type I diabetes or diabetic ketoacidosis


Reportable Dosage Form &Strength

       Tablets:100mg、300mg


Mechanism of Action

Sodium-glucose linked transporter, SGLT is a kind of glucose transporter. There are two subtypes, SGLT1 and SGLT2, which are distributed in small intestinal mucosa and renal tubules respectively, and can transport glucose into blood. Canagliflozin can inhibit SGLT2, so that glucose in renal tubules can not be re absorbed into the blood smoothly and excreted with urine, thus reducing the blood glucose concentration.

Development Progress】

         Ready to declare



2、Domestic Declaration



Declaration Type

Reportable Dosage Form

Number of Declared Preparations

Enterprises

5+3Tablet

Tablets:1

imported

、21 

domestic

Compound tablets: 1 domestic

Total: 0




 Brinzolamide 布林佐胺 CAS号:138890-62-7

Guangzhou Tosun Pharmaceutical Ltd

FL 4-5,No.3, 2nd Kehui street, Science Park, Guangzhou High-tech Industrial Development Zone, Guangzhou, China. 510663

Tel: +86-20-66392521; Fax: +86-20-66392525

Canagliflozin is a SGLT2 inhibitor drug, which can reduce blood sugar by removing glucose from the body through the kidney after glucose decomposition. In addition to good blood glucose control, canagliflozin (canagliflozin) has the most remarkable effect of weight loss and few hypoglycemic events, which has a broad prospect.


Effective treatment of type II diabetes in adult patients


热门关键词: 进口原料药代理 印度进口原料药 原料药关联审评 进口药品注册代理 国内参比制剂 美国参比制剂 原料药注册服务 原料药联合申报 原料药供应商
Copyright ©2020 Guangzhou Tosun Pharmaceutical Ltd 粤ICP备16102594号-2
MapsXML Maps  Maps
Phone

(86)18922121079

(86)18026299762

TOP